Which Patients With MASLD Need Fibrosis Assessment?

Who should enter the pathway?

The pathway is especially relevant for people with type 2 diabetes, obesity with additional metabolic risk factors, incidentally noted steatosis, or persistent unexplained aminotransferase elevation. Repeated normal ALT values do not exclude fibrosis, particularly in diabetes and obesity.

Why FIB-4 comes first

FIB-4 uses age, AST, ALT and platelet count. It is not a diagnostic test for MASH, but it performs well as a rule-out tool for advanced fibrosis. AASLD materials commonly use <1.3 as a low-risk threshold in adults aged 35-65. Patients with type 2 diabetes or multiple metabolic risk factors should be reassessed more frequently than metabolically lower-risk patients.

When FIB-4 is not low

A FIB-4 of 1.3 or greater should generally lead to a secondary test rather than immediate biopsy. VCTE is widely available and practical; ELF is another validated option, while MR elastography offers high accuracy when results are discordant or the clinical stakes are high. A FIB-4 above approximately 2.67 substantially increases concern for advanced fibrosis.

Age matters

FIB-4 can overclassify older adults because age is part of the equation and can underperform in younger adults. AASLD educational guidance uses an age-adjusted lower-risk threshold around 2.0 in those older than 65 and recommends alternative assessment when a younger patient has meaningful clinical risk despite a low FIB-4.

Repeat testing is part of care

A low-risk result is not a lifetime clearance. Metabolic disease changes over time. People with diabetes or multiple metabolic risk factors typically warrant repeat assessment every 1-2 years; lower-risk patients can often be reassessed less frequently.

A practical clinical approach

1. Identify patients with steatosis, metabolic risk or unexplained aminotransferase elevation.
2. Calculate FIB-4 unless age/clinical context makes it unreliable.
3. If clearly low risk, manage metabolic disease and repeat risk assessment at an appropriate interval.
4. If FIB-4 is indeterminate/high, obtain VCTE, ELF or another validated secondary assessment.
5. Refer patients with high-risk or discordant results, suspected advanced fibrosis or cirrhosis, or diagnostic uncertainty.

Common errors to avoid

• Using ALT alone to decide who has significant liver disease.
• Sending every intermediate FIB-4 directly to biopsy.
• Ignoring the age effect on FIB-4.
• Failing to repeat fibrosis assessment as diabetes, weight and metabolic risk evolve.

What should trainees remember?

FIB-4 is a triage tool. Its clinical value comes from identifying who can remain in lower-intensity follow-up and who needs a second-stage fibrosis test.

Free further reading from Dr. Alan B. R. Thomson

See Dr. Thomson's Guideline-Based Management in Hepatology and Best Practice Guidelines in Hepatopancreaticobiliary Disorders.

Frequently asked questions

What FIB-4 is considered low risk?

For many adults aged 35-65, <1.3 is used as a low-risk threshold.

What should happen if FIB-4 is 1.3 or higher?

Use a secondary fibrosis assessment such as VCTE rather than diagnosing advanced fibrosis from FIB-4 alone.

Does a normal ALT rule out advanced fibrosis?

No.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.

2. Thomson ABR. Best Practice Guidelines in Hepatopancreaticobiliary Disorders. CAPstone Academic Publishers; 2024. ISBN 979-8861272735.

3. Rinella ME, et al. AASLD Practice Guidance. Hepatology. 2023;77:1797-1835.

4. AASLD Liver Fellow Network. Spare Me the Jab: Noninvasive Assessment of Patients with MASLD. 2023.

5. AASLD Liver Fellow Network. Why Are Non-invasive Risk Scores Such as FIB-4 Used in Clinical Practice?